Northstar All themes →
Home / Themes / Healthcare

Digital Health

Digital Health & Med-TechHealthcare Updated 2026-07-23

Digital health has split into two very different growth stories under one label: mature enterprise software (Veeva, Doximity) compounding steadily at scale, and a new generation of employer-sponsored chronic-care platforms (Hinge Health, Omada Health) growing 40%+ and turning profitable within a year of going public.

📈 What changed: Hinge Health raised full-year 2026 guidance to $818-824M revenue (40% YoY growth) and a 27% non-GAAP operating margin at its inaugural Investor Day on June 9, 2026, citing rising…

The Northstar view

Primary State
Two-Speed Market ActiveMature enterprise software vs. fast-growing chronic-care pure-plays
Near-Term Value
Recurring Enterprise & Subscription Revenue Active$3.2B (Veeva) down to $78-182M quarterly (Omada/Hinge), all recurring
Main Risk
Customer Concentration WatchOmada: two Cigna-affiliated partners = 64% of Q1 2026 receivables
Conviction
High StableHigh for the enterprise layer, building for pure-plays — Veeva/Doximity proven; Hinge/Omada still scaling repeatable growth
Next Trigger
ACCESS Model cohort 2 (Jan 2027) / Q2 2026 earnings 2027-01Cohort 1 launched July 5, 2026 without Hinge Health or Omada Health, who both cited insufficient Medicare payment rates

Six-indicator scorecard

IndicatorScoreReading
Maturity
higher is better · high confidence
78/100
Scaled at the enterprise-software layer (Veeva, Doximity) but genuinely fragmented across sub-verticals with no converged design.
Evidence Strength
higher is better · high confidence
80/100
SEC filings for the fastest-growing names give the strongest possible evidentiary base in this rubric.
Commercial Proximity
higher is better · high confidence
78/100
Real, disclosed recurring revenue across the cohort, with the newest public pure-plays growing fastest.
Capital & Policy Support
higher is better · medium confidence
38/100
Commercially, not publicly, funded — the emerging tailwind is US value-based reimbursement rather than direct subsidy.
Crowding Risk
lower is better · high confidence
50/100
A mixed basket: newly-public pure-plays are still building institutional ownership while incumbents are steady, well-covered names.
Reflexivity Risk
lower is better · high confidence
33/100
Largely earnings-grounded and increasingly self-funding as the newest public names turn cash-generative.

Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.

Related tickers

VEEVDOCSHNGEOMDAAAPLGOOGLGEHCPHIA.ASDXCMHIMSFDHTHTEC

See the full Digital Health briefing

The public page is the summary (backed by 11 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.

Open in the appStart free →

The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.

More in Healthcare

GLP-1 & the Metabolic Health RevolutionGLP-1 receptor agonists have become the fastest-adopted drug class in pharmaceutical hist…Longevity Biotech & the Biology of AgeingLongevity biotech is transitioning from high-concept science to early-stage clinical vali…Precision MedicineGenomic, molecular and AI-driven diagnostics are converging into a single treatment-selec…Diagnostic GenomicsLiquid biopsy and NGS-based screening are moving cancer detection upstream of diagnosis —…Gene EditingGene editing has crossed from proof-of-concept to a genuine, if still narrow, commercial…Cell TherapyCell therapy has moved past proof-of-concept into a genuine multi-billion-dollar commerci…mRNA TherapeuticsThe mRNA platform that COVID built is now being redirected at oncology and rare disease,…AI Drug DiscoveryAI drug discovery has attracted more capital in 2026 than any biotech subsector since imm…